Changing patterns of gynaecological cancer incidence and mortality in Sri Lanka, 2005–2022: a national population-based registry study

Background Gynaecological cancers are an important public health concern, yet evidence on their epidemiological patterns and temporal trends in Sri Lanka remains limited. This study evaluated trends in incidence and mortality and characterised histological patterns across gynaecological cancer sites. Methods This population-based study used Sri Lanka cancer registry data and national mortality data for 2005–2022. Age-standardised incidence (ASIR) and mortality (ASMR) rates were calculated using the World Health Organization world standard population. Joinpoint regression was used to estimate annual and average annual percent changes (APC/AAPC) with 95% confidence intervals. Histological distribution was assessed for the major cancer sites. Results A total of 48,603 gynaecological cancer cases were recorded, led by cervical (n = 18,013), ovarian (n = 15,765), and uterine (n = 12,766) cancers. Overall ASIR increased from 18.62 to 29.95 per 100,000, with an AAPC of 3.25% (95% CI: 2.30–4.41; p < 0.001). Uterine cancer showed the steepest increase (AAPC 8.21%; 95% CI: 7.01, 10.04; p < 0.001), followed by ovarian cancer, whereas cervical cancer incidence remained stable (p = 0.53). Vulval, vaginal, and other unspecified female genital cancers also showed significant increases in age-standardised incidence. Uterine cancer accounted for the highest number of deaths (n = 4,115) with a non-significant decline (AAPC − 0.80%). Cumulative risk increased most markedly for corpus uteri cancer, with significant trends in both age groups, and for vaginal cancer among women aged 0–74 years. Histology was predominantly squamous cell carcinoma for cervical cancer (77.8%), while adenomas and adenocarcinomas predominated in uterine corpus cancer (73.1%). Cystic, mucinous, and serous neoplasms were the most common ovarian histological group (44.1%). Conclusion Sri Lanka's gynaecological cancer burden is shifting, with a growing contribution from uterine and ovarian cancers alongside a persistent cervical cancer burden, in the context of demographic and metabolic transitions. These findings support strengthening organised cervical cancer screening and sustained human papillomavirus vaccination while expanding diagnostic and treatment capacity for uterine and ovarian cancers.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11532403/v1
Primary Topic
Global Cancer Incidence and Screening
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Changing patterns of gynaecological cancer incidence and mortality in Sri Lanka, 2005–2022: a national population-based registry study

Y. M. T. Y. Wijeratne, SL Jayakody, RMBS Weerasooriya, CNRA Alles et al.
Research Square
Global Cancer Incidence and Screening
preprint

Changing patterns of gynaecological cancer incidence and mortality in Sri Lanka, 2005–2022: a national population-based registry study

Y. M. T. Y. Wijeratne, SL Jayakody, RMBS Weerasooriya, CNRA Alles, N. S. Soysa
preprint en

Abstract

Background Gynaecological cancers are an important public health concern, yet evidence on their epidemiological patterns and temporal trends in Sri Lanka remains limited. This study evaluated trends in incidence and mortality and characterised histological patterns across gynaecological cancer sites. Methods This population-based study used Sri Lanka cancer registry data and national mortality data for 2005–2022. Age-standardised incidence (ASIR) and mortality (ASMR) rates were calculated using the World Health Organization world standard population. Joinpoint regression was used to estimate annual and average annual percent changes (APC/AAPC) with 95% confidence intervals. Histological distribution was assessed for the major cancer sites. Results A total of 48,603 gynaecological cancer cases were recorded, led by cervical (n = 18,013), ovarian (n = 15,765), and uterine (n = 12,766) cancers. Overall ASIR increased from 18.62 to 29.95 per 100,000, with an AAPC of 3.25% (95% CI: 2.30–4.41; p < 0.001). Uterine cancer showed the steepest increase (AAPC 8.21%; 95% CI: 7.01, 10.04; p < 0.001), followed by ovarian cancer, whereas cervical cancer incidence remained stable (p = 0.53). Vulval, vaginal, and other unspecified female genital cancers also showed significant increases in age-standardised incidence. Uterine cancer accounted for the highest number of deaths (n = 4,115) with a non-significant decline (AAPC − 0.80%). Cumulative risk increased most markedly for corpus uteri cancer, with significant trends in both age groups, and for vaginal cancer among women aged 0–74 years. Histology was predominantly squamous cell carcinoma for cervical cancer (77.8%), while adenomas and adenocarcinomas predominated in uterine corpus cancer (73.1%). Cystic, mucinous, and serous neoplasms were the most common ovarian histological group (44.1%). Conclusion Sri Lanka's gynaecological cancer burden is shifting, with a growing contribution from uterine and ovarian cancers alongside a persistent cervical cancer burden, in the context of demographic and metabolic transitions. These findings support strengthening organised cervical cancer screening and sustained human papillomavirus vaccination while expanding diagnostic and treatment capacity for uterine and ovarian cancers.

Research Square
University of Peradeniya (LK), Teaching Hospital Kandy (LK)
Global Cancer Incidence and Screening
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon